232 related articles for article (PubMed ID: 23260229)
21. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
22. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
van Harten J
Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
[TBL] [Abstract][Full Text] [Related]
24. The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line.
Hansen CH; Larsen LW; Sørensen AM; Halling-Sørensen B; Styrishave B
Toxicol In Vitro; 2017 Jun; 41():1-11. PubMed ID: 28179152
[TBL] [Abstract][Full Text] [Related]
25. Serotonin regulates osteoclast differentiation through its transporter.
Battaglino R; Fu J; Späte U; Ersoy U; Joe M; Sedaghat L; Stashenko P
J Bone Miner Res; 2004 Sep; 19(9):1420-31. PubMed ID: 15312242
[TBL] [Abstract][Full Text] [Related]
26. Are pharmacokinetic drug interactions with the SSRIs an issue?
Brøsen K
Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
[TBL] [Abstract][Full Text] [Related]
27. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
Hirano K; Kimura R; Sugimoto Y; Yamada J; Uchida S; Kato Y; Hashimoto H; Yamada S
Br J Pharmacol; 2005 Mar; 144(5):695-702. PubMed ID: 15678084
[TBL] [Abstract][Full Text] [Related]
28. Selective Serotonin Reuptake Inhibitors.
Lochmann D; Richardson T
Handb Exp Pharmacol; 2019; 250():135-144. PubMed ID: 30838457
[TBL] [Abstract][Full Text] [Related]
29. FLUOXETINE modifies the expression of serotonergic markers in a differentiation-dependent fashion in the mesencephalic neural cell line A1 mes c-myc.
Di Lieto A; Leo D; Volpicelli F; di Porzio U; Colucci-D'Amato L
Brain Res; 2007 Apr; 1143():1-10. PubMed ID: 17321503
[TBL] [Abstract][Full Text] [Related]
30. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells.
Ishima T; Fujita Y; Hashimoto K
Eur J Pharmacol; 2014 Mar; 727():167-73. PubMed ID: 24508523
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology and pharmacokinetics of citalopram and other SSRIs.
Baumann P
Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():5-11. PubMed ID: 8732438
[TBL] [Abstract][Full Text] [Related]
32. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Baumann P; Rochat B
Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
[TBL] [Abstract][Full Text] [Related]
33. The effects of serine proteinase inhibitors on bone resorption in vitro.
Tumber A; Papaioannou S; Breckon J; Meikle MC; Reynolds JJ; Hill PA
J Endocrinol; 2003 Sep; 178(3):437-47. PubMed ID: 12967336
[TBL] [Abstract][Full Text] [Related]
34. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
[TBL] [Abstract][Full Text] [Related]
35. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
36. Block of volume-regulated anion channels by selective serotonin reuptake inhibitors.
Maertens C; Droogmans G; Verbesselt R; Nilius B
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):158-65. PubMed ID: 12122503
[TBL] [Abstract][Full Text] [Related]
37. The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
J Pharm Pharmacol; 2001 Apr; 53(4):449-61. PubMed ID: 11341361
[TBL] [Abstract][Full Text] [Related]
38. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Finley PR
Ann Pharmacother; 1994 Dec; 28(12):1359-69. PubMed ID: 7696728
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat.
Mos J; Mollet I; Tolboom JT; Waldinger MD; Olivier B
Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):123-35. PubMed ID: 10082238
[TBL] [Abstract][Full Text] [Related]
40. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
Owens MJ; Knight DL; Nemeroff CB
Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
